Key Points
➤ The clinical burden associated with the treatment of melanoma has
been increasing due to rising incidence in most countries worldwide.
➤ In less than ten years, nine new drugs have been approved for
unresectable melanoma, along with four new approvals in the adjuvant
setting.
➤ Overall survival for melanoma is improving equally rapidly, with
dramatic increases in long-term survival observed from administration
of these new therapies.
Treatment
Neoadjuvant Systemic Therapy
Cutaneous Melanoma Eligible for Resection
➤ Recommendation 1. No recommendation can be made for or against the
routine use of neoadjuvant therapy for adults with resectable regional or
distant metastatic cutaneous melanoma at this time. Patients should be
offered or referred for enrollment in clinical trials where possible. (L)
Adjuvant Systemic Therapy
Resected (Stage II, III, IV) Cutaneous Melanoma
➤ Recommendation 2.1. Adjuvant pembrolizumab, nivolumab, or
combination dabrafenib and trametinib therapy should NOT be offered
to patients with resected stage II melanoma outside of enrollment in a
clinical trial. (Moderate recommendation; IC-L)
